Regulus Therapeutics Inc
RGLS8.160USD
+0.020+0.25%
Horário de mercado （ET）Cotações atrasadas em 15 min
540.87MValor de mercado
PerdaP/L TTM
Mais detalhes de Regulus Therapeutics Inc Empresa
Regulus Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing drugs targeting microRNAs to treat diseases with significant unmet medical need. The Company is focused on orphan kidney diseases where microRNA genetic drivers are implicated and there are clear unmet medical needs. Its product candidate, RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), is in Phase 1b clinical development. In addition to this program, the Company continues to advance and expand its internal discovery pipeline to identify potential product candidates. microRNAs are naturally occurring ribonucleic acid (RNA) molecules that play a critical role in regulating key biological pathways. ADPKD is among the common human monogenic disorders and a cause of end-stage renal disease.
Informações da empresa
Código da empresaRGLS
Nome da EmpresaRegulus Therapeutics Inc
Data de listagemOct 04, 2012
CEOMr. Joseph P. (Jay) Hagan
Número de funcionários34
Tipo de títulosOrdinary Share
Fim do ano fiscalOct 04
Endereço4224 Campus Point Court
CidadeSAN DIEGO
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal92121
Telefone18582026300
Sitehttps://www.regulusrx.com/
Código da empresaRGLS
Data de listagemOct 04, 2012
CEOMr. Joseph P. (Jay) Hagan
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Ms. Crispina Calsada, CPA
Ms. Crispina Calsada, CPA
Chief Financial Officer
Chief Financial Officer
56.73K
+24.74%
Mr. Christopher Ray Aker, J.D.
Mr. Christopher Ray Aker, J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
50.55K
+402.65%
Mr. John Mckenna
Mr. John Mckenna
President, Director
President, Director
--
--
Mr. Eduard Marti
Mr. Eduard Marti
Director
Director
--
--
Ms. Rekha Garg
Ms. Rekha Garg
Chief Medical Officer
Chief Medical Officer
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Ms. Crispina Calsada, CPA
Ms. Crispina Calsada, CPA
Chief Financial Officer
Chief Financial Officer
56.73K
+24.74%
Mr. Christopher Ray Aker, J.D.
Mr. Christopher Ray Aker, J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
50.55K
+402.65%
Mr. John Mckenna
Mr. John Mckenna
President, Director
President, Director
--
--
Mr. Eduard Marti
Mr. Eduard Marti
Director
Director
--
--
Ms. Rekha Garg
Ms. Rekha Garg
Chief Medical Officer
Chief Medical Officer
--
--
Detalhamento da receita
FY2021
FY2020
FY2019
Sem dados
Por RegiãoUSD
Nome
Receita
Proporção
United States
0.00
0.00%
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: qui, 3 de jul
Atualizado em: qui, 3 de jul
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Federated Hermes Global Investment Management Corp.
22.85%
New Enterprise Associates (NEA)
9.34%
Octagon Capital Advisors LP
6.70%
The Vanguard Group, Inc.
5.71%
BlackRock Institutional Trust Company, N.A.
5.53%
Other
49.87%
Investidores
Investidores
Proporção
Federated Hermes Global Investment Management Corp.
22.85%
New Enterprise Associates (NEA)
9.34%
Octagon Capital Advisors LP
6.70%
The Vanguard Group, Inc.
5.71%
BlackRock Institutional Trust Company, N.A.
5.53%
Other
49.87%
Tipos de investidores
Investidores
Proporção
Investment Advisor/Hedge Fund
31.40%
Hedge Fund
24.30%
Venture Capital
13.25%
Investment Advisor
12.88%
Individual Investor
0.80%
Research Firm
0.77%
Bank and Trust
0.11%
Pension Fund
0.08%
Other
16.42%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
1
--
0.00%
-90.00
2025Q1
151
57.15M
82.75%
-7.04M
2024Q4
137
55.74M
85.10%
-6.54M
2024Q3
128
58.95M
90.05%
-6.89M
2024Q2
113
63.43M
96.89%
+3.08M
2024Q1
85
60.55M
95.51%
+47.86M
2023Q4
70
12.67M
62.78%
-270.56K
2023Q3
77
12.73M
68.68%
-335.94K
2023Q2
80
12.00M
64.97%
-983.27K
2023Q1
89
9.82M
61.73%
-1.56M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Federated Hermes Global Investment Management Corp.
15.82M
22.85%
+2.97M
+23.09%
Mar 31, 2025
New Enterprise Associates (NEA)
6.47M
9.34%
--
--
Mar 31, 2025
Octagon Capital Advisors LP
4.64M
6.7%
-211.73K
-4.37%
Mar 31, 2025
The Vanguard Group, Inc.
3.95M
5.71%
-14.97K
-0.38%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
3.83M
5.53%
-64.74K
-1.66%
Mar 31, 2025
Point72 Asset Management, L.P.
3.68M
5.32%
+1.71M
+87.10%
Apr 01, 2025
Deep Track Capital LP
3.26M
4.71%
--
--
Mar 31, 2025
Vivo Capital, LLC
2.70M
3.89%
-2.30M
-46.07%
Mar 31, 2025
Baker Bros. Advisors LP
2.69M
3.89%
+2.69M
--
Mar 31, 2025
Geode Capital Management, L.L.C.
1.30M
1.88%
+21.49K
+1.68%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: dom, 6 de jul
Atualizado em: dom, 6 de jul
Nome
Proporção
iShares Micro-Cap ETF
0.11%
iShares Russell 2000 Value ETF
0.03%
Global X Russell 2000 ETF
0.02%
iShares Russell 2000 ETF
0.02%
ProShares UltraPro Russell2000
0.02%
ProShares Hedge Replication ETF
0.02%
Proshares Ultra Russell 2000
0.02%
iShares Russell 2000 Growth ETF
0.01%
iShares Core S&P Total U.S. Stock Market ETF
0%
Avantis US Small Cap Equity ETF
0%
iShares Micro-Cap ETF
Proporção0.11%
iShares Russell 2000 Value ETF
Proporção0.03%
Global X Russell 2000 ETF
Proporção0.02%
iShares Russell 2000 ETF
Proporção0.02%
ProShares UltraPro Russell2000
Proporção0.02%
ProShares Hedge Replication ETF
Proporção0.02%
Proshares Ultra Russell 2000
Proporção0.02%
iShares Russell 2000 Growth ETF
Proporção0.01%
iShares Core S&P Total U.S. Stock Market ETF
Proporção0%
Avantis US Small Cap Equity ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Jun 28, 2022
Merger
10<1
Jun 28, 2022
Merger
10<1
Jun 28, 2022
Merger
10<1
Jun 28, 2022
Merger
10<1
Data
Tipo
Proporção
Jun 28, 2022
Merger
10<1
Jun 28, 2022
Merger
10<1
Jun 28, 2022
Merger
10<1
Jun 28, 2022
Merger
10<1
